Skip to content

Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain

Intra-operative Ketamine Infusions in Patients With Chronic Lower Back Discomfort Undergoing Laminectomies.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00899600
Enrollment
102
Registered
2009-05-12
Start date
2007-02-28
Completion date
2009-04-30
Last updated
2018-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low Back Pain

Keywords

chronic pain, back surgery, opioid dependent, NMDA receptor antagonism, Ketamine, Central sensitization

Brief summary

Noxious stimuli occurring intraoperatively and postoperatively generate central sensitization, decreasing pain thresholds and ultimately increasing analgesic requirements. The pathophysiology of central sensitization is thought to involve excitatory amino acid receptors such as N-methyl-d-aspartate (NMDA) (1, 2). Ketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist that has been shown to be useful in the reduction of acute postoperative pain and analgesic consumption in a variety of surgical interventions (3). Spine surgery provides a unique opportunity to evaluate the preemptive and preventative impact of ketamine on the primary end points of postoperative 24 and 48 hour opioid consumption in patients with chronic pain. The goal of this double blinded, prospective, randomized placebo controlled trial is to quantify the preemptive and preventative analgesic effects of ketamine infusions in this patient population. Such insight may lead to better pain control, improved satisfaction, and ultimately a reduction in side-effects related to postoperative opioid use.

Detailed description

Noxious stimuli occurring intra-operatively and post-operatively generate central sensitization, decreasing pain thresholds and ultimately increasing analgesic requirements. The pathophysiology of central sensitization is thought to involve excitatory amino acid receptors that have been implicated in the prolongation of painful states in animal models. The N-methyl-d-aspartate (NMDA) receptor is one such excitatory amino acid receptor (1, 2). The underlying mechanism of central sensitization is thought to involve c-fiber associated injury occurring with incision. Crile and Wall brought about the concept that attenuation of central sensitization could be accomplished via the provision of analgesic interventions (opioids, local anesthesia) prior to the noxious insult. They termed the central sensitization attenuation preemptive analgesia. The concept of preemptive analgesia was later expanded to implicate both pre and post-incisional noxious stimuli as part of this process, resulting in studies designed to provide interventions throughout the surgical intervention (peri-procedural) (3). Reduction in analgesic requirements or pain scores for more than five half-lives (1st order kinetics) following the provision of the intervening analgesic agent peri-procedurally is now known as preventative analgesia. The term preemptive analgesia is now reserved for interventions that occur only before the noxious stimuli. Multiple studies have investigated the concepts of preemptive analgesia and preventative analgesia by providing a variety of analgesic interventions at various times throughout the surgical insult in addition to more conventional means of anesthesia provision, including opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAID)s, Cyclooxygenase-II (COX-2) inhibitors, alpha-2 agonists, and ketamine (4, 5, 6). Preemptive and preventative analgesia using a variety of pharmacological agents with at least partially known mechanisms of actions has provided some insight into potential mechanisms of central sensitization. Ketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist that has been shown to be useful in the reduction of acute postoperative pain and analgesic consumption in a variety of surgical interventions with variable routes of administration. It has also been shown to be effective in the presence and absence of opioids, suggesting that it has more than one mechanism of action in preemptive and preventative analgesia, including but not limited to decreasing central excitability, decreasing acute post-operative opioid tolerance, and a possible modulation of opioid receptors (7). Ketamine is a common anesthetic agent and has been in use since the Vietnam War. Clinically, ketamine provides pain relief with minimal respiratory depression, and at higher doses (1-2mg/kg) can induce general anesthesia while maintaining blood pressure and cardiac output. Recently, a qualitative systematic review of the role of NMDA receptor antagonists was completed. Twenty-four studies investigating the role of ketamine met the inclusion criteria of the study, 58% of which demonstrated a preemptive or preventative analgesic effect. Patients underwent a variety of surgical procedures, both ambulatory and inpatient, and there was no obvious effect of either surgical type or dose of ketamine (range 0.15 to 1mg/kg) on the success of preventative intervention. However, the authors were unable to quantify the degree of reduction in primary end-points (opioid consumption, pain scores, both) due to variability in recording of such data. In addition, most inpatient studies were limited to abdominal procedures while the outpatient studies investigated mainly knee arthroscopies, providing no insight into the degree of impact of NMDA receptor antagonism in the setting of high pre-operative opioid tolerance combined with surgical procedures known to be associated with an invariably high degree of post-operative pain. Of note, only 1/24 studies documented a significant difference in side effects related to ketamine provision in patients who had received 20mg of epidural ketamine (7). Laminectomy procedures provide a unique opportunity to evaluate the preemptive and preventative impact of ketamine on the primary end points of acute post-operative pain scores and opioid consumption in a patient population with opioid dependence and a high degree of post-operative and intra-operative noxious stimuli. The goal of this double blinded, randomized placebo controlled trial will be to test for the presence of, and quantify, the preemptive and preventative analgesic effects of ketamine infusions in this patient population. Such insight may lead to better pain control, improved satisfaction, and ultimately a reduction in side-effects related to post-operative opioid use including but not limited to respiratory depression, constipation, and delirium.

Interventions

DRUGKetamine

Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure

OTHERNormal saline

Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).

Sponsors

Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Laminectomy procedures. * History of chronic back pain. * Daily opioid use. * Capable of providing informed consent.

Exclusion criteria

* Intolerance/allergy to ketamine. * Intolerance/true allergy to morphine. * Elevated intra-ocular pressure. * Uncontrolled hypertension. * Elevated intra-cranial pressure. * Any history of a psychosis. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Morphine Consumption in the First 48 Hours After Surgery48 hoursTotal morphine(mg)consumed at 48 hours.

Secondary

MeasureTime frameDescription
Hospital DurationDischarge from hospital, approximately 2 days after surgery
Hemodynamic Changes - Heart RateBaseline, Inoperative (approximately) 48 hoursHemodynamic change (Heart Rate) from baseline in the intraoperative and 48-h postoperative periods
Hemodynamic Changes - Blood PressureBaseline, Inoperative (approximately) 48 hoursHemodynamic change (Blood Pressure) from baseline in the intraoperative and 48-h postoperative periods
Percentage of Participants With Complications/Adverse Events48 hours and 6 weeksAdverse events

Countries

United States

Participant flow

Recruitment details

The study was conducted over a two-year period (February 2007 to April 2009) at Dartmouth-Hitchcock Medical Center. Approval was obtained from the Committee for Protection of Human Subjects (Lebanon, NH, United States of America). Informed patient consent was obtained from all patients.

Pre-assignment details

Three hundred and one patients were screened. Of these patients, 165 (55%) were eligible for enrollment. Sixty-one percent of eligible patients were randomized to one of the two treatment groups. No patients enrolled in the study were excluded from the primary analysis.

Participants by arm

ArmCount
Normal Saline
Normal saline : Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
50
Ketamine52
Total102

Baseline characteristics

CharacteristicTotalNormal SalineKetamine
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
20 Participants8 Participants12 Participants
Age, Categorical
Between 18 and 65 years
82 Participants42 Participants40 Participants
Age, Continuous51.6 years
STANDARD_DEVIATION 14.3
51.4 years
STANDARD_DEVIATION 14.4
51.7 years
STANDARD_DEVIATION 14.2
Region of Enrollment
United States
102 participants50 participants52 participants
Sex: Female, Male
Female
41 Participants22 Participants19 Participants
Sex: Female, Male
Male
61 Participants28 Participants33 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
4 / 505 / 52
serious
Total, serious adverse events
0 / 500 / 52

Outcome results

Primary

Morphine Consumption in the First 48 Hours After Surgery

Total morphine(mg)consumed at 48 hours.

Time frame: 48 hours

Population: See methodology

ArmMeasureValue (MEAN)Dispersion
Normal SalineMorphine Consumption in the First 48 Hours After Surgery309 mgStandard Deviation 341
KetamineMorphine Consumption in the First 48 Hours After Surgery195 mgStandard Deviation 111
Secondary

Hemodynamic Changes - Blood Pressure

Hemodynamic change (Blood Pressure) from baseline in the intraoperative and 48-h postoperative periods

Time frame: Baseline, Inoperative (approximately) 48 hours

Population: Analysis included only a subgroup of participants who had not used non-steroidals (NSAIDS).

ArmMeasureGroupValue (MEAN)Dispersion
Normal SalineHemodynamic Changes - Blood PressureBaseline systolic blood pressure133.8 mmHgStandard Deviation 19.5
Normal SalineHemodynamic Changes - Blood PressureBaseline diatolic blood pressure81.3 mmHgStandard Deviation 12.8
Normal SalineHemodynamic Changes - Blood PressureInteroperative Systolic blood pressure139.6 mmHgStandard Deviation 16.7
Normal SalineHemodynamic Changes - Blood PressureInteroperative diastolic blood pressure80.8 mmHgStandard Deviation 13.2
Normal SalineHemodynamic Changes - Blood Pressure48-hours post operative systolic blood pressure133 mmHgStandard Deviation 16.4
Normal SalineHemodynamic Changes - Blood Pressure48-hours post operative diastolic blood pressure75.9 mmHgStandard Deviation 8.9
KetamineHemodynamic Changes - Blood Pressure48-hours post operative systolic blood pressure129.7 mmHgStandard Deviation 12.2
KetamineHemodynamic Changes - Blood PressureBaseline systolic blood pressure132.2 mmHgStandard Deviation 16.9
KetamineHemodynamic Changes - Blood PressureInteroperative diastolic blood pressure77.8 mmHgStandard Deviation 13.7
KetamineHemodynamic Changes - Blood PressureBaseline diatolic blood pressure77.3 mmHgStandard Deviation 11.3
KetamineHemodynamic Changes - Blood Pressure48-hours post operative diastolic blood pressure75.6 mmHgStandard Deviation 8.6
KetamineHemodynamic Changes - Blood PressureInteroperative Systolic blood pressure139.9 mmHgStandard Deviation 18.3
Secondary

Hemodynamic Changes - Heart Rate

Hemodynamic change (Heart Rate) from baseline in the intraoperative and 48-h postoperative periods

Time frame: Baseline, Inoperative (approximately) 48 hours

Population: Analysis included only a subgroup of participants who had not used non-steroidals (NSAIDS).

ArmMeasureGroupValue (MEAN)Dispersion
Normal SalineHemodynamic Changes - Heart RateBaseline Peak Heart Rate77.3 beats per minuteStandard Deviation 13.5
Normal SalineHemodynamic Changes - Heart RateInteroperative Peak Heart Rate91.4 beats per minuteStandard Deviation 13.67
Normal SalineHemodynamic Changes - Heart Rate48-hours Post Operative98.6 beats per minuteStandard Deviation 13.4
KetamineHemodynamic Changes - Heart RateBaseline Peak Heart Rate74 beats per minuteStandard Deviation 13.9
KetamineHemodynamic Changes - Heart RateInteroperative Peak Heart Rate87.6 beats per minuteStandard Deviation 13.72
KetamineHemodynamic Changes - Heart Rate48-hours Post Operative99.8 beats per minuteStandard Deviation 20.2
Secondary

Hospital Duration

Time frame: Discharge from hospital, approximately 2 days after surgery

ArmMeasureValue (MEAN)Dispersion
Normal SalineHospital Duration4571 minutesStandard Deviation 4099
KetamineHospital Duration4364 minutesStandard Deviation 2296
Secondary

Percentage of Participants With Complications/Adverse Events

Adverse events

Time frame: 48 hours and 6 weeks

ArmMeasureGroupValue (NUMBER)
Normal SalinePercentage of Participants With Complications/Adverse EventsNausea, 48 hours22.5 Percent
Normal SalinePercentage of Participants With Complications/Adverse EventsVomiting, 48 hours12.2 Percent
Normal SalinePercentage of Participants With Complications/Adverse EventsHallucinations, 48 hours2.0 Percent
Normal SalinePercentage of Participants With Complications/Adverse EventsUrinary Retention, 48 hours2.0 Percent
Normal SalinePercentage of Participants With Complications/Adverse EventsNausea, 6 weeks17.0 Percent
Normal SalinePercentage of Participants With Complications/Adverse EventsVomiting, 6 weeks8.5 Percent
Normal SalinePercentage of Participants With Complications/Adverse EventsHallucinations, 6 weeks23.4 Percent
Normal SalinePercentage of Participants With Complications/Adverse EventsUrinary Retention, 6 weeks57.5 Percent
KetaminePercentage of Participants With Complications/Adverse EventsUrinary Retention, 6 weeks45.1 Percent
KetaminePercentage of Participants With Complications/Adverse EventsNausea, 48 hours26.9 Percent
KetaminePercentage of Participants With Complications/Adverse EventsNausea, 6 weeks11.8 Percent
KetaminePercentage of Participants With Complications/Adverse EventsVomiting, 48 hours15.4 Percent
KetaminePercentage of Participants With Complications/Adverse EventsHallucinations, 6 weeks11.8 Percent
KetaminePercentage of Participants With Complications/Adverse EventsHallucinations, 48 hours1.9 Percent
KetaminePercentage of Participants With Complications/Adverse EventsVomiting, 6 weeks9.8 Percent
KetaminePercentage of Participants With Complications/Adverse EventsUrinary Retention, 48 hours7.7 Percent

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026